Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients

被引：9

作者：

Shi, Y. ^{[1
,2
]}

Xing, P. ^{[1
,2
]}

Han, X. ^{[3
,4
]}

Wang, S. ^{[5
]}

Liu, Y. ^{[1
,2
]}

Liu, P. ^{[1
,2
]}

Li, J. ^{[1
,2
]}

Chang, L. ^{[5
]}

Guan, Y. ^{[5
]}

Zhang, Z. ^{[1
,2
]}

Wu, D. ^{[1
,2
]}

Yao, J. ^{[1
,2
]}

Xin, Y. ^{[5
]}

机构：

[1] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing, Peoples R China

[2] Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China

[3] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Dept Clin Lab, Beijing, Peoples R China

[4] Peking Union Med Coll, Beijing 100021, Peoples R China

[5] Geneplus Beijing Inst, Beijing, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

plasma ctDNA; non-small cell lung cancer; Resistance;

D O I：

10.1016/j.jtho.2018.08.875

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.13-18

引用

页码：S589 / S589

页数：1

共 50 条

[41] Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation
Kay, Maryam
Dehghanian, Fariba
JOURNAL OF MOLECULAR MODELING, 2017, 23 (11)
[42] Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation
Maryam Kay
Fariba Dehghanian
Journal of Molecular Modeling, 2017, 23
[43] Analysis of ctDNA using the mFastSeqS and plasma-Seq methods for screening and therapy monitoring in prostate cancer patients
Belic, Jelena
Heitzer, Ellen
Ulz, Peter
Auer, Martina
Fischereder, Katja
Bauernhofer, Thomas
Geigl, Jochen B.
Speicher, Michael R.
CLINICAL CANCER RESEARCH, 2016, 22
[44] Capture-based ultra-deep sequencing in plasma ctDNA reveals the resistance mechanism of ALK inhibitors in a patient with advanced ALK-positive NSCLC
Guo, Jing
Guo, Lihong
Sun, Li
Wu, Zhenzhen
Ye, Junyi
Liu, Jing
Zuo, Qiang
CANCER BIOLOGY & THERAPY, 2018, 19 (05) : 359 - 363
[45] Comprehensive plasma genotyping of patients with EGFR positive NSCLC as a monitoring tool for therapy response and disease progression
Shafi, Gowhar
Behel, Vichitra
Bharade, Atul
Bhonde, Mandar
Patil, Vijay Maruti
Noronha, Vanita
Chougule, Anuradha
Chandrani, Pratik
Kaushal, Rajiv Kumar
Prajapati, Sangeeta
Ratnaparkhi, Mrunal
Hariramani, Kanchan
Mobeen, Fauzul
Basavalingegowda, Madhura
Uttarwar, Mohan
Bose, Chirantan
Prabhash, Kumar
Khandare, Jayant
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
Ntzifa, Aliki
Kotsakis, Athanasios
Georgoulias, Vassilis
Lianidou, Evi
CANCERS, 2021, 13 (11)
[47] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
D. Zheng
X. Ye
M. Z. Zhang
Y. Sun
J. Y. Wang
J. Ni
H. P. Zhang
L. Zhang
J. Luo
J. Zhang
L. Tang
B. Su
G. Chen
G. Zhu
Y. Gu
J. F. Xu
Scientific Reports, 6
[48] Detection of EGFR mutations in plasma cfDNA and paired CTCs of NSCLC patients before and after osimertinib therapy using crystal digital PCR
Ntzifa, Aliki
Kotsakis, Athanasios
Georgoulias, Vassilis
Lianidou, Evi
CANCER RESEARCH, 2022, 82 (12)
[49] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
Zheng, D.
Ye, X.
Zhang, M. Z.
Sun, Y.
Wang, J. Y.
Ni, J.
Zhang, H. P.
Zhang, L.
Luo, J.
Zhang, J.
Tang, L.
Su, B.
Chen, G.
Zhu, G.
Gu, Y.
Xu, J. F.
SCIENTIFIC REPORTS, 2016, 6
[50] Detection, dynamic monitoring, and resistance mechanism exploration of genomic alterations in circulating cell free tumor DNA (ctDNA) in Chinese metastatic breast cancer (mBC).
Li, Huiping
Yu, Jianjun
Liu, Xiao-Ran
Wang, Amy
Zhao, Zhixin
Cheung, Tak
Shi, Wei-Jie
Zhang, Yue
Zhang, Phoebe
Tan, Meng-Yao
Du, Peter
Kong, Wei-yao
Liu, Ya-Xin
Zhang, Jia-yang
Yan, Ying
Jia, Shidong
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →